SCHEMBL756243

SCHEMBL756243

COc1ccc(CN(Cc2ccc(OC)cc2)c2nc(C)nc(-c3c(Cl)nc4ccc(F)cn34)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.46
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
MAPT P10636 2/20 0.33
LMNA P02545 1/20 0.33
NR1H4 Q96RI1 2/20 0.33
CETP P11597 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HIF1A Q16665 1/20 0.32
HSD17B10 Q99714 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MET P08581 1/20 0.32
GAA P10253 1/20 0.32
RAB9A P51151 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756821 0.84 PIK3CA (0.47) PIK3CAMAPTLMNAALDH1A1HPGD
SCHEMBL752702 0.80 PIK3CA (0.52) PIK3CAPIK3CD
SCHEMBL168801 0.75 PIK3CA (0.49) PIK3CACYP11B1CYP11B2MAPTLMNA
SCHEMBL114357 0.71 PIK3CA (0.77) PIK3CAMAPTLMNAALDH1A1CYP1A2
SCHEMBL166618 0.71 PIK3CA (0.56) PIK3CAMAPTLMNAALDH1A1CYP1A2
SCHEMBL116255 0.71 PIK3CA (0.49) PIK3CACYP11B1CYP11B2MAPTLMNA
SCHEMBL116627 0.71 PIK3CA (0.49) PIK3CAMAPTLMNAALDH1A1CYP1A2
SCHEMBL115289 0.71 PIK3CA (0.48) PIK3CAMAPTLMNAALDH1A1CYP1A2
SCHEMBL114555 0.70 LMNA (0.49) PIK3CAMAPTLMNAALDH1A1CYP1A2
SCHEMBL115485 0.69 PIK3CA (0.52) PIK3CACYP11B1CYP11B2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885CYP11B1 1090/4885CYP11B2 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.